Shilpa Medicare Limited (NSE: SHILPAMED) announced on June 30, 2026, that its subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for an intravenous (IV) nivolumab biosimilar. This partnership aims to widen patient access to advanced immuno-oncology therapy across Europe, leveraging the loss of exclusivity of the originator nivolumab to increase patient access to a high-quality, EU-GMP-manufactured biosimilar.

Strategic Collaboration

Under the agreement, Orion will hold the exclusive right to register, market, distribute, and sell the nivolumab biosimilar across Europe, acting as the Marketing Authorization holder in the territory. Shilpa Biologicals will lead product development and serve as the exclusive long-term commercial manufacturer and supplier for the European market from its advanced biologics facility in Dharwad, India. The partnership combines Shilpa’s manufacturing capabilities with Orion’s commercial and regulatory expertise.

Market Opportunity

Nivolumab, a blockbuster PD-1 immunotherapy, recorded sales of approximately USD4.1 billion in 2025, underscoring the scale of the opportunity that high-quality biosimilars can unlock for patients and healthcare systems across Europe. This deal marks another chapter in a fast-growing relationship between Shilpa Medicare Limited and Orion Corporation, following their earlier collaboration to bring Shilpa’s Recombinant Human Albumin to Europe.

Future Prospects

As a result, Shilpa Medicare Limited is poised to make advanced medicines more affordable and accessible worldwide. Vishnukant Bhutada, Managing Director of Shilpa Medicare, stated, ‘Extending our partnership with Orion into immuno-oncology is a defining moment for Shilpa Biologicals. It reflects the trust our partners place in our quality, our science, and our ability to deliver complex biologics at scale — and it moves us closer to our mission of making advanced medicines affordable and accessible worldwide.’ The agreement is expected to create broader access to affordable quality medicines across Europe.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Shilpa Medicare Limited

Shilpa Medicare Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Shilpa gains 64.4% over three months and trades near its 52-week highs. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. No meaningful dividend — total return is entirely dependent on capital appreciation. Buyers show up with 1.8x the volume of sellers. Moreover, they dominated on 15 of recent sessions versus 14 for sellers — a healthy accumulation pattern. The stock rises 64.4% in three months on 13.8% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Shilpa Medicare Limited.